127 related articles for article (PubMed ID: 31691051)
21. Facile one-pot synthesis and antimycobacterial evaluation of pyrazolo[3,4-d]pyrimidines.
Trivedi A; Dodiya D; Surani J; Jarsania S; Mathukiya H; Ravat N; Shah V
Arch Pharm (Weinheim); 2008 Jul; 341(7):435-9. PubMed ID: 18574851
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity.
Martins F; Santos S; Ventura C; Elvas-Leitão R; Santos L; Vitorino S; Reis M; Miranda V; Correia HF; Aires-de-Sousa J; Kovalishyn V; Latino DA; Ramos J; Viveiros M
Eur J Med Chem; 2014 Jun; 81():119-38. PubMed ID: 24836065
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and antimycobacterial activity of some novel imidazo[1,2-c]pyrimidines.
Chhabria MT; Jani MH
Eur J Med Chem; 2009 Oct; 44(10):3837-44. PubMed ID: 19423196
[TBL] [Abstract][Full Text] [Related]
24. Pyrazole clubbed triazolo[1,5-a]pyrimidine hybrids as an anti-tubercular agents: Synthesis, in vitro screening and molecular docking study.
Bhatt JD; Chudasama CJ; Patel KD
Bioorg Med Chem; 2015 Dec; 23(24):7711-6. PubMed ID: 26631439
[TBL] [Abstract][Full Text] [Related]
25. Mechanistic investigation of the oxidation of hydrazides: implications for the activation of the TB drug isoniazid.
Amos RI; Gourlay BS; Yates BF; Schiesser CH; Lewis TW; Smith JA
Org Biomol Chem; 2013 Jan; 11(1):170-6. PubMed ID: 23165368
[TBL] [Abstract][Full Text] [Related]
26. Peptide conjugates of therapeutically used antitubercular isoniazid-design, synthesis and antimycobacterial effect.
Horváti K; Mezo G; Szabó N; Hudecz F; Bosze S
J Pept Sci; 2009 May; 15(5):385-91. PubMed ID: 19319854
[TBL] [Abstract][Full Text] [Related]
27. Rational design of isonicotinic acid hydrazide derivatives with antitubercular activity: Machine learning, molecular docking, synthesis and biological testing.
Kovalishyn V; Grouleff J; Semenyuta I; Sinenko VO; Slivchuk SR; Hodyna D; Brovarets V; Blagodatny V; Poda G; Tetko IV; Metelytsia L
Chem Biol Drug Des; 2018 Jul; 92(1):1272-1278. PubMed ID: 29536635
[TBL] [Abstract][Full Text] [Related]
28. A green expedient synthesis of pyridopyrimidine-2-thiones and their antitubercular activity.
Rajesh SM; Kumar RS; Libertsen LA; Perumal S; Yogeeswari P; Sriram D
Bioorg Med Chem Lett; 2011 May; 21(10):3012-6. PubMed ID: 21498077
[TBL] [Abstract][Full Text] [Related]
29. Fragment-Based Design of
Sabbah M; Mendes V; Vistal RG; Dias DMG; Záhorszká M; Mikušová K; Korduláková J; Coyne AG; Blundell TL; Abell C
J Med Chem; 2020 May; 63(9):4749-4761. PubMed ID: 32240584
[TBL] [Abstract][Full Text] [Related]
30. Novel pyrazine based anti-tubercular agents: Design, synthesis, biological evaluation and in silico studies.
Hassan NW; Saudi MN; Abdel-Ghany YS; Ismail A; Elzahhar PA; Sriram D; Nassra R; Abdel-Aziz MM; El-Hawash SA
Bioorg Chem; 2020 Mar; 96():103610. PubMed ID: 32028062
[TBL] [Abstract][Full Text] [Related]
31. Synthesis, In silico Molecular Docking and Pharmacokinetic Studies, In vitro Antimycobacterial and Antimicrobial Studies of New Imidozolones Clubbed with Thiazolidinedione.
Khan IH; Patel NB; Patel VM
Curr Comput Aided Drug Des; 2018; 14(4):269-283. PubMed ID: 29766819
[TBL] [Abstract][Full Text] [Related]
32. New one-pot synthesis of anti-tuberculosis compounds inspired on isoniazid.
Ghiano DG; Recio-Balsells A; Bortolotti A; Defelipe LA; Turjanski A; Morbidoni HR; Labadie GR
Eur J Med Chem; 2020 Dec; 208():112699. PubMed ID: 32927391
[TBL] [Abstract][Full Text] [Related]
33. Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents.
Lokesh BVS; Prasad YR; Shaik AB
Infect Disord Drug Targets; 2019; 19(3):310-321. PubMed ID: 30556506
[TBL] [Abstract][Full Text] [Related]
34. Bis dihydropyrimidine: synthesis and antimycobacterial activity.
Ali MA; Manogaran E; Govindasamy J; Sellappan V; Pandian S
J Enzyme Inhib Med Chem; 2011 Feb; 26(1):149-53. PubMed ID: 20583864
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and in vitro and in vivo antimycobacterial activity of isonicotinoyl hydrazones.
Sriram D; Yogeeswari P; Madhu K
Bioorg Med Chem Lett; 2005 Oct; 15(20):4502-5. PubMed ID: 16115763
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, antitubercular activity and molecular docking study of substituted [1,3]dioxino[4,5-
Venkatesh T; Bodke YD; Manjunatha B; Ravi Kumar S
Nucleosides Nucleotides Nucleic Acids; 2021; 40(11):1037-1049. PubMed ID: 34470580
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and mechanistic investigation of iron(II) complexes of isoniazid and derivatives as a redox-mediated activation strategy for anti-tuberculosis therapy.
Laborde J; Deraeve C; de Mesquita Vieira FG; Sournia-Saquet A; Rechignat L; Villela AD; Abbadi BL; Macchi FS; Pissinate K; Bizarro CV; Machado P; Basso LA; Pratviel G; de França Lopes LG; Sousa EHS; Bernardes-Génisson V
J Inorg Biochem; 2018 Feb; 179():71-81. PubMed ID: 29175704
[TBL] [Abstract][Full Text] [Related]
38. Pharmacoinformatics-based identification of anti-bacterial catalase-peroxidase enzyme inhibitors.
Jangam CS; Bhowmick S; Chorge RD; Bharatrao LD; Patil PC; Chikhale RV; AlFaris NA; ALTamimi JZ; Wabaidur SM; Islam MA
Comput Biol Chem; 2019 Dec; 83():107136. PubMed ID: 31630014
[TBL] [Abstract][Full Text] [Related]
39. Mutations in catalase-peroxidase KatG from isoniazid resistant Mycobacterium tuberculosis clinical isolates: insights from molecular dynamics simulations.
Pimentel AL; de Lima Scodro RB; Caleffi-Ferracioli KR; Siqueira VL; Campanerut-Sá PA; Lopes LD; de Almeida AL; Cardoso RF; Seixas FA
J Mol Model; 2017 Apr; 23(4):121. PubMed ID: 28303436
[TBL] [Abstract][Full Text] [Related]
40. Novel dihydropyrimidines as a potential new class of antitubercular agents.
Trivedi AR; Bhuva VR; Dholariya BH; Dodiya DK; Kataria VB; Shah VH
Bioorg Med Chem Lett; 2010 Oct; 20(20):6100-2. PubMed ID: 20813528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
